ARTICLE | Clinical News

ACH-3102: Additional Phase II data

October 13, 2014 7:00 AM UTC

Additional data from 12 treatment-naive patients with HCV genotype 1 infection in the open-label, partial-crossover Phase II proxy study showed that once-daily 50 mg ACH-3102 plus 400 mg Sovaldi sofosbuvir for 8 weeks led to an SVR 8 weeks after the end of treatment in 100% of patients. Achillion will present SVR12 data from the first 12 patients at the American Association for the Study of Liver Diseases meeting in Boston in November. Based on SVR4 data from the first 12 patients reported in August, Achillion said 12 additional patients are receiving the combination once daily for 6 weeks (see BioCentury, Aug. 18). SVR4 data from the 6-week cohort are expected by year end. ...